👋 Hey, let’s get into it. GLP-1 drugs have already transformed diabetes, obesity, and pharma earnings calls. Now researchers think they may be influencing something else entirely: mood.

A new study suggests GLP-1 therapies may alleviate depression not by acting directly on the brain, but by reshaping the gut microbiome. Researchers found that semaglutide and liraglutide boosted populations of Lactobacillus delbrueckii, a bacterium that produces compounds linked to improved mood and reduced depressive behaviors in mice.

The ad basically writes itself: want to be skinny and happy? Take GLP-1s.

💰 GSK Pays $10.6B for Nuvalent to Strengthen Its Oncology Pipeline
GSK is making its biggest acquisition in more than a decade, agreeing to acquire cancer-focused biotech Nuvalent for $10.6 billion in cash. The deal gives GSK two late-stage targeted lung cancer programs, including neladalkib, which is currently under FDA review with a November decision date. As patent cliffs loom for GSK's HIV franchise later this decade, the company is clearly prioritizing clinically de-risked oncology assets with near-term commercial potential. Investors approved of the move, sending Nuvalent shares up roughly 39%.

🧠 Lilly Licenses Alzheimer's Program from AlzeCure in Potential $1B Deal
Eli Lilly is adding another Alzheimer's shot on goal through a licensing agreement with Sweden's AlzeCure Pharma. The deal centers on ACD860, a gamma-secretase modulator designed to reduce production of the amyloid-beta protein Aβ42 while increasing potentially beneficial amyloid fragments. Lilly is paying just $10 million upfront, but milestones could exceed $1 billion. With the Alzheimer's market expected to expand dramatically over the next decade, Lilly appears determined to build one of the industry's deepest neurodegeneration pipelines.

🧪 Novartis Expands Molecular Glue Ambitions with Orionis Deal Worth Up to $1.4B
Novartis is doubling down on molecular glues, signing a second collaboration with Orionis Biosciences that includes $40 million upfront and up to $1.4 billion in milestones. Molecular glues work by forcing proteins to interact in ways nature never intended, creating new opportunities against historically difficult drug targets. The collaboration combines Orionis' Allo-Glue platform with AI-driven discovery tools, highlighting how large pharma continues to chase next-generation protein degradation and targeted protein modulation technologies.

🇩🇪 Pfizer Warns Germany's Drug Pricing Reforms Could Jeopardize Future Investment
Germany's proposed healthcare reforms are facing growing pushback from the pharmaceutical industry. Pfizer CEO Albert Bourla reportedly warned Chancellor Friedrich Merz that planned drug pricing changes could undermine the predictability required for long-term investment decisions. The reforms aim to reduce healthcare spending by more than €16 billion next year, including significant savings from pharmaceuticals. With multiple drugmakers already scaling back investment plans, Germany's balancing act between cost containment and innovation incentives is drawing increasing scrutiny.

💻 100+ ChatGPT Prompts to Revolutionize Your Day
Discover how you can leverage ChatGPT to boost efficiency, streamline tasks, and stay ahead in your industry. Supercharge your productivity with HubSpot's comprehensive guide.

📈 Parabilis Rockets to $4B Valuation in IPO
Cancer-focused Parabilis Medicines surged as much as 67% after raising nearly $745 million in an upsized IPO and private placement.

🚫 WuXi AppTec Lands on Pentagon Blacklist
WuXi AppTec's addition to the Pentagon's Chinese military companies list could intensify Biosecure Act concerns for U.S. customers.

📄 Lilly Files Oral GLP-1 Foundayo for Diabetes
Lilly's oral GLP-1 Foundayo outperformed semaglutide and other competitors across multiple Phase 3 diabetes studies.

💊 Merck and Gilead Advance Weekly HIV Pill
Positive Phase 3 results position islatravir and lenacapavir to become the first once-weekly oral HIV treatment.

🙌 AstraZeneca's Oral GLP-1 Delivers Double-Digit Weight Loss
AZ's elecoglipron produced up to 11.8% weight loss in Phase 2 while showing no signs of plateauing.

🫧 SonoThera Raises $125M for Bubble-Based Gene Delivery
The biotech's oversubscribed financing will push Duchenne muscular dystrophy and kidney disease programs into the clinic.

🛑 Sanofi Stops Autoimmune Phase 3 Trial Early
An interim analysis found Sanofi's autoimmune candidate was unlikely to achieve sufficient efficacy, prompting an early halt.

For decades, biotech companies have searched for ways to make drugs more effective, easier to administer, and cheaper to manufacture. The next breakthrough might not come from a new AI platform or gene editing technology. It might come from outer space.

A growing group of companies believes microgravity could solve one of pharma's most frustrating problems: crystallization. On Earth, gravity causes particles to settle, fluids to circulate unevenly, and proteins to form imperfect structures. In orbit, those same molecules can assemble into remarkably uniform crystals. The result is potentially more stable medicines, lower viscosity formulations, and drugs that are easier for patients to take.

Companies like SpaceMD are already putting the idea to work. The company has flown dozens of automated micro-labs into orbit and tested nearly 40 drug compounds, including collaborations with Eli Lilly and Bristol Myers Squibb. The goal isn't science fiction. It's creating drug formulations that can turn lengthy hospital infusions into simple injections.

The concept isn't entirely new. Merck experimented with protein crystal growth aboard the International Space Station more than a decade ago while studying Keytruda. Insights from those experiments ultimately helped inform an injectable version of the blockbuster cancer drug, which received FDA approval last year.

Others are pushing even further. Varda is building autonomous manufacturing satellites capable of producing pharmaceutical ingredients in orbit and returning them to Earth. Instead of selling spacecraft, Varda's pitch is simple: send us your drug candidate and we'll send back a better version.

There are still plenty of challenges. Launch costs remain high. Regulatory pathways are largely untested. And many scientists remain skeptical that space-based manufacturing can scale economically.

But biotech has always been a business of improbable ideas becoming billion-dollar industries. If microgravity can reliably improve how drugs are made, the next great pharmaceutical manufacturing hub may not be Boston, San Diego, or Basel…It may be low Earth orbit.

That's how much EY expects biotech revenues to grow in 2026, marking a third consecutive year of expansion. Licensing deals, M&A activity, IPOs, and venture funding are all showing renewed strength. The industry still faces patent cliffs, pricing pressure, and regulatory uncertainty, but for the first time in a while, optimism appears to be outpacing anxiety.

Here’s what biotech Redditors are talking about:

😡 My PI Said I Just Ruined My Big Pharma Career
One Reddit post struck a nerve this week after a longtime academic researcher described receiving a warning from their PI after accepting a startup job. The PI allegedly threatened to tell industry contacts about the researcher and effectively try to blacklist them from future pharma opportunities, claiming they were leaving at the "wrong time." The biotech community overwhelmingly sided with the employee. Industry veterans pointed out that hiring decisions rarely hinge on a single person's opinion and that proactively trashing former employees usually damages the manager's reputation more than the candidate's. The consensus: congratulations on the new job, and maybe mute that former boss.

📱 AstraZeneca Employees Learn the First Rule of Pharma Social Media
Reddit had plenty of jokes after AstraZeneca was reprimanded again over employees engaging with company-related LinkedIn posts. What followed was an impromptu support group for pharma workers navigating social media compliance rules. Many described training sessions that ultimately convinced them the safest strategy was simply not interacting with anything remotely related to their employer. To sum it up: “Rule 1 of pharma social media: don't engage with pharma social media. Rule 2: this doesn’t apply to BioNucleus content.” 😁

🚀 Biotech Wants Its Own Space Race
A newly formed biotech advocacy group wants the U.S. to adopt a national biotech strategy similar to China's innovation playbook.

📺 Skyrizi and Tremfya Battle for TV Dominance
AbbVie's Skyrizi barely edged out J&J's Tremfya in May ad spending, winning by roughly $100,000 with a total spend of $38.9 million.

🏭 Hikma Expands Ohio Manufacturing Footprint
Hikma will invest $267 million across Ohio facilities, adding 350 jobs and expanding domestic manufacturing capacity.

🇪🇸 Ona Therapeutics Raises $87M to Build the Next Generation of ADCs
Barcelona-based Ona Therapeutics has raised $86.6 million to advance a pair of antibody-drug conjugates targeting advanced breast and colorectal cancers. Rather than chasing crowded ADC targets, the company is focusing on proteins found primarily on resistant tumor cells and rarely in healthy tissue. Its lead program, ONA-255, is aimed at hormone receptor-positive, HER2-negative metastatic breast cancer, a setting where treatment options become increasingly limited after standard therapies fail. It's a differentiated strategy in one of biotech's hottest sectors.

🧫 June 11, 1937 - The Birth of the Man Who Proved Ulcers Were Bacterial
On this day in 1937, Australian pathologist Robin Warren was born in Adelaide, Australia. Decades later, Warren and Barry Marshall would overturn one of medicine's most entrenched beliefs by proving that stomach ulcers were primarily caused by the bacterium Helicobacter pylori, not stress or spicy food. The discovery transformed treatment for millions of patients and earned the pair the 2005 Nobel Prize in Medicine. It's a reminder that sometimes the biggest breakthroughs begin with questioning something everyone "knows" is true.

One of this week's stories featured pharma employees getting compliance training on why they shouldn't "like" a LinkedIn post about their company's drug.

Meanwhile, somewhere on TikTok, a supplement influencer is explaining how a proprietary blend of mushroom powder, sea moss, and positive vibes cured their brain fog, fixed their posture, and improved their relationship with their landlord.

Different regulatory environments, I suppose.

That’s all for today. See you Tuesday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead

BioNucleus Briefing lands in the inboxes of scientists, founders, investors, operators, and industry decision-makers twice a week.

If you'd like to sponsor a future issue, just hit reply and let's talk.